
Chinese pharmaceutical group established on 15 November 2017 at 219 Furong Middle Fourth Road in the Xishan Economic and Technological Development Zone in Wuxi, Jiangsu, with about 334.8 million yuan of registered capital and Zhou Zhuohe as legal representative. Combines research, manufacturing and sales of active pharmaceutical ingredients and finished medicines as a high technology innovative pharmaceutical group. Its subsidiary Wuxi Fuqi Pharmaceutical is a Jiangsu high-tech and science and technology innovation enterprise that has passed European Union GMP certification six consecutive times, won the China Pharmaceutical Quality Award in 2016 and cleared a United States FDA inspection in 2017.
Để lại đánh giá